The results showed that low expression of p16 was correlated with poor PFS in patients with bladder cancer, and the heterogeneity was eliminated (HR = 1.84, 95% CI = 1.13~3.01, and P = 0.015; I2 = 0%, P = 0.487) (Figure 3(c)). The gene discussed is CDKN2A; the disease is urinary bladder cancer.